Vertex Pharmaceuticals Inc

NASDAQ:VRTXUnited States

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Contact Information

Headquarters

50 Northern AvenueBOSTON, MA, United States 02210

Phone

617-341-6393

Fax

---

Executives

Executive Chairman of the Board

Jeffrey Leiden

President, Chief Executive Officer, Director

Reshma Kewalramani

Chief Financial Officer, Executive Vice President

Charles Wagner

Chief Operating Officer, Executive Vice President

Stuart Arbuckle

Executive Vice President - Global Research, Chief Scientific Officer

David Altshuler